Peter Schmid, MD, PhD
In light of the results of the IMpassion130 trial, the combination of atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) is poised to become the new frontline standard of care for patients with metastatic triple-negative breast cancer (TNBC) with PD-L1–positive tumors. Lead author Peter Schmid, MD, PhD, said that these results have created an opportunity to improve outcomes for patients with TNBC.
IMpassion130 evaluated the added benefit of the checkpoint inhibitor atezolizumab to standard nab-paclitaxel chemotherapy in patients with metastatic TNBC with the endpoints of progression-free survival (PFS) and overall survival (OS).
Findings presented at the 2018 ESMO Congress showed that in patients who tested positive for PD-L1 expression, the median PFS was 7.5 months (95% CI, 6.7-9.2) with atezolizumab plus nab-paclitaxel versus 5.0 months (95% CI, 3.8-5.6) with chemotherapy (HR, 0.62; 95% CI, 0.49-0.78; P
<.0001). This was the most compelling result, said Schmid. Additionally, the 1-year PFS rates were of note, with a PFS of 29% (95% CI, 22%-36%) for atezolizumab plus nab-paclitaxel and 16% (95% CI, 11%-22%) for nab-paclitaxel alone.
... to read the full story